The use of Mitomycin-C to reduce synechia in middle meatus in sinus surgery: preliminary results.
Synechia is the most frequent complication after sinus surgery and has been reported in up to 36% of cases. Several types of materials have been used to reduce the incidence of synechia, including Mitomycin C (MMC). This prospective study aimed to assess the effectiveness of topical MMC in the prevention of synechia after sinus surgery in humans. At the end of surgery, MMC solution (1.0 mg/ml) was topically applied randomly to one of the middle meatuses (MMC group) of 14 patients while saline solution was applied to the contralateral meatus (control group). The author remained blind to the medicated side. Synechiae were classified as partial or total. Three patients had middle meatus synechia in the MMC group (21.43%) versus nine (64.29%) in the control group (p = 0.054). In the MMC group, all three middle meatus synechia were partial, while in the control group there were four partial (28.57%) and five total (35.71%) cases of synechia (p = 0.025). Mitomycin C was not effective in preventing middle meatus synechia, but reduced the probability of total synechia formation.